Cipla’s Active Pharmaceutical Ingredient (API) division plays a critical role in supporting the company’s mission to deliver affordable, high-quality medicines across diverse therapeutic areas worldwide. Backed by a team of over 300 skilled scientists, Cipla drives innovation through advanced research, robust process development, and a commitment to quality by design.

With state-of-the-art R&D facilities across three locations in India, Cipla’s API capabilities span synthetic and organic chemistry, process engineering, and analytical development. Its expanding pipeline includes more than 75 complex API developments across key therapeutic areas such as oncology, Hepatitis C, antiretrovirals (ARV), diabetology, cardiovascular (CVS), central nervous system (CNS), and respiratory care.

Cipla leverages advanced technologies—including process analytical technology and continuous flow reactors—to enhance efficiency, scalability, and consistency in API development. Through the integration of design of experiments (DOE) and quality-by-design principles, the company ensures reliable, cost-effective processes from early development through commercialization.

Dedicated oncology and polypeptide laboratories further strengthen Cipla’s capabilities, while its Integrated Product Development (IPD) team advances sustainability through green chemistry initiatives. By incorporating enzymatic transformations, waste reduction strategies, and input recycling, Cipla is committed to environmentally responsible manufacturing.

Supported by a highly advanced analytical research infrastructure—including NMR, LC-MS/MS, GC-MS, PXRD, and single crystal XRD—Cipla delivers precision and quality across a wide spectrum of API complexity, from simple molecules to highly complex multi-chiral compounds.